Prospective Observational Trial to Evaluate Quality of Life After Definitive Chemoradiation in Patients With Anal Cancer (LANACARE)

Launched by LUDWIG-MAXIMILIANS - UNIVERSITY OF MUNICH · Jan 2, 2019

Keywords

ClinConnect Summary

The LANACARE trial is studying how patients with anal cancer feel and function after receiving a specific treatment called definitive chemoradiation, which combines chemotherapy and radiation therapy. The goal is to understand the quality of life of these patients over time by using standardized questionnaires that ask about their physical and emotional well-being. This research will also look at how effective the treatment is and any side effects that patients may experience.

To participate in the trial, you must be at least 18 years old, have been diagnosed with anal cancer that hasn't spread to other parts of the body, and be recommended for this treatment by a team of doctors. You’ll need to give your written consent and be able to answer the questionnaires provided. The study is currently recruiting participants, and everyone, regardless of gender, is welcome to join. Throughout the trial, you can expect regular check-ins and support as researchers gather important information to improve future care for anal cancer patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • histologically proven anal cancer without distant metastases
• • indication for definitive chemoradiation therapy based on multidisciplinary evaluation
• • age \>=18 years
• • written informed consent
• • ability to answer the standardized questionaires according to the treating physician
• Exclusion Criteria:
• • age \< 18 years
• • prior systemic therapy with regard to anal cancer
• • distant metastases
• • second malignancy